Harpoon Therapeutics Says AbbVie Declines to Exercise License Option
14 9월 2023 - 5:55AM
Dow Jones News
By Ben Glickman
Harpoon Therapeutics said on Wednesday that AbbVie won't
exercise its exclusive license option on Harpoon's HPN217
program.
The South San Francisco, Calif.-based immuno-oncology company
said that AbbVie had the option under an agreement between the two
companies, which is set to expire Oct. 12. Harpoon said that it
plans to complete the current Phase 1 trial in order to continue
development.
Harpoon's HPN217 program targets B cell maturation antigen.
Chief Executive Julie Eastland said that the preliminary data
"continue to be encouraging with a favorable safety profile."
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
September 13, 2023 16:40 ET (20:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Harpoon Therapeutics (NASDAQ:HARP)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Harpoon Therapeutics (NASDAQ:HARP)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024